Overview

Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases

Status:
Not yet recruiting
Trial end date:
2023-07-15
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, multi-center, single-arm clinical trial
Phase:
Phase 2
Details
Lead Sponsor:
Zhejiang Cancer Hospital
Collaborator:
Jiangsu Hansoh Pharmaceutical Co., Ltd.